>>
Home > Principal Investigators > Aleix Prat

PRINCIPAL INVESTIGATORS

Aleix Prat
ALEIX PRAT

LinkedIn

ALEIX PRAT

Current positions

  • Principal Investigator, VHIO´s Translational Genomics Group
  • Specialist physician in Breast Cancer
  • 2014-Head, Medical Oncology Department at the Hospital Clinic de Barcelona. Spain 
  • Evaluator of project proposals for the "National Evaluation and Foresight Agency (ANEP)" of the Spanish Ministry of Science and Innovation. Spain (since 2014).
  • 2014- Associate Professor. University of Barcelona, Faculty of Medicine, Barcelona, Spain.
  • 2015- Scientific Committee Coordinator of the Spanish Breast Cancer Cooperative Research Group (SOLTI), Spain.
  • 2015- Co-Coordinator of the Oncology and Haematology Research Area Num. 5. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Hospital Clinic de Barcelona. Barcelona, Spain.
  • Head. Translational Genomics and Targeted Therapeutics in Solid Tumors Group. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Hospital Clínic de Barcelona. Barcelona, Spain

Academic Qualifications

  • 2003. Degree in Medicine and Surgery. a Universitat de Barcelona (UB). Spain
  • 2008. Board Certified in Medical Oncology. Ministerio de Sanidad y Consumo. Spain
  • 2008. Diploma of Advanced Studies (DEA). Universitat Autònoma de Barcelona (UAB). Spain
  • 2006-2008. Master in Molecular Oncology. Spanish National Cancer Research Centre (CNIO). Spain
  • 2006-2008. Master in Molecular Oncology. Spanish National Cancer Research Centre (CNIO). Spain
  • 2008-2012. Postdoctoral Research Training at Lineberger Comprehensive Cancer Center [C.M. Perou´s Laboratory]. University of North Carolina, NC, USA
  • 2013.Doctor in Medicine (PhD). Universitat Autònoma de Barcelona (UAB). Spain

Areas of Research

  • Cancer Genomics
  • Biomarker Discovery
  • Breast Cancer
  • Clinical Trials

Prizes and Scholarships

  • 2009. Merit Award. American Society of Clinical Oncology (ASCO) Annual Meeting
  • 2010. Scholar-in-Training Award. American Association for Cancer Research (AACR)
  • 2011. Nominated for BioMed Central Open Data Award
  • 2011. Merit Award. ASCO Annual Meeting.
  • 2011. Spanish Medical Oncology Society (SEOM) Grant in Translational Research (€70.000)
  • 2012. ROCHE Grant in Translational Cancer Research (€77.000)
  • 2012. Travel Grant from IMPAKT 2012 Breast Cancer Meeting
  • 2012. International Award for Breast Cancer Research, Padova, Italy.
  • 2013 Programa Estatal de Fomento de la Investigación Científica y Tecnológica. Proyectos de investigación en salud (€205.000).
  • 2013 Susan G. Komen Career Catalyst Grant ($450.000).
  • 2014 Spanish Medical Oncology Society (SEOM) Grant. Proyectos de investigación en salud (€40.000).
  • 2015 Extraordinary Doctorate Award (2013).Universitat Autònoma de Barcelona. UAB.
  • 2015 Biomedical Research Grants 2015. Fundación Eugenio Rodriguez Pascual - FERP (18.000€).
  • 2015 Extraordinary Doctorate Award (2013). Universitat Autònoma de Barcelona. UAB.
     

Most relevant scientific publications

  • Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Álvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón Y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clin Cancer Res. 2016;22(3):560-566. Epub 2015 Jul 7.
  • Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015;13:303.
  • Vidal M, Peg V, Galván P, Tres A, Cortés J, Ramón y Cajal S, Rubio IT, Prat A. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. Mol Oncol. 2015;9(6):1081-1090.
  • Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26-S35.
  • Prat A*; Cheang MCU; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S. Intrinsic Subtype, Prognosis and Benefit of Lapatinib in First-Line Hormone Receptor-Positive Metastatic Breast Cancer Treated with Letrozole. JAMA Oncol. June09, 2016. doi:10.1001/jamaoncol.2016. 0922. *Correspondence Author. 
  • Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM and Baselga J. Molecular Features and Survival Outcomes of the Intrinsic Subtypes within HER2-Positive Breast Cancer. J Natl Cancer Inst. 2014.
  • Prat A, Cheang MC, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemical-defined Luminal A breast cancer. J Clin Oncol 2013 Jan 10;31(2):203-9
  • The Cancer Genome Atlas Project. Comprehensive molecular portraits of human breast tumors. Nature. 2012 Oct 4;490(7418):61-70.
  • Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and Molecular Characterization of the Claudin-low Intrinsic Subtype of Breast Cancer. Breast Cancer Res. 2010. 12(5):R68.

All publications

  • Prat A, Felip E. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. Cancer & Chemotherapy Rev 2006;1:5-12.
  • Prat A, Peralta S, Cuéllar H, Ocana A. Hepatic Pneumatosis As a Complication of an Abdominal Desmoid Tumor. J Clin Oncol 2007;25(7):897-898.
  • Felip E, Cedrés S, Peralta S, Prat A. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC). Ann Oncol. 2007 Jul;18 Suppl 9:ix143-146.
  • Prat A, Baselga J. Biologic therapy: Current and Future Applications in Oncology. Med Clin (Barc). 2007 Jun 30;129(5):184-93.
  • Prat A, Martínez P, Serrano C, Montero MA, Andreu J, Cortés J. Acute Lung Injury Associated with Docetaxel and Bevacizumab. Clin Oncol (R Coll Radiol). 2007 Dec;19(10):803-5.
  • Prat A, Casado E, Cortés J. New Approaches in Angiogenic Targeting in Colorectal Carcinoma. World J Gastroenterol. 2007 Nov 28;13(44):5857-5866.
  • Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J; Huguet J, Del Campo J. Successful Treatment of Pulmonary Metastatic Salivary Ductal Carcinoma (SDC) with Trastuzumab-Based Therapy. Head Neck. 2008 May;30(5):680-3.
  • Prat A, Parera M, Peralta S, Perez-Benavente M, Roxana I, Garcia A, Martinez-Palones J, Gil A, Baselga J, Del Campo J. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol. 2008 Feb;19(2):327-31.
  • Prat A, Parera M, Del Campo JM. The role of CA-125 in stage IV epithelial ovarian cancer. J Clin Oncol 2008;26(10):1771-1772.
  • Muñoz E, Prat A, Adamo B, Peralta S, Ramon y Cajal S, Valverde C. A Rare Case of Malignant Solitary Fibrous Tumor of the Spinal Cord. Spine. 2008 May 20;33(12):E397-9.
  • Prat A, Serrano C, Valverde C, Calvo E. Acute severe hypothyroidism induced by sunitinib. Radiother Oncol. 2008 Oct;89(1):124-5. Epub 2008 May 24.
  • Del Campo JM, Prat A, Gil-Moreno Antonio, Pérez J, Parera M. An Update of Novel Therapeutic Agents for Cervical Cancer. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6.
  • Prat A, Baselga J. The Role of Hormonal Therapy in the Management of Hormonal Receptor Positive Breast Cancer with Coexpression of HER2. Nat Clin Pract Oncol. 2008 Sep;5(9):531-42.
  • Prat A, Parera M, Adamo B, Peralta S, Perez-Benavente M, Garcia A, Martinez-Palones J, Gil A, Baselga J, Del Campo J. Risk of Recurrence during Follow-up for Optimally Treated Advanced Epithelial Ovarian Cancer with a Low-Level Increase of Serum CA-125 Levels. Ann Oncol. 2009 Feb;20(2):294-7.
  • Cedrés S, Prat A, Martínez P, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients with second-third line erlotinib. Lung Cancer. 2009 Nov;66(2):257-61. Epub 2009 Feb 23.
  • Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med. 2009 Aug:15(8):842-844.
  • Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical Implementation of the Intrinsic Molecular Subtypes of Breast Cancer. Lancet Oncol. 2010 Aug;11(8):718-9
  • Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011 Feb;5(1):5-23.
  • Fan C*, Prat A*, Parker J, Liu Y, Carey LA, Troester MA and Perou CM. Building Prognostic Models for Breast Cancer Patients Using Clinical Variables and Hundreds of Gene Expression Signatures. BMC Med Genomics 2011 Jan 9;4(1):3.
  • Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and Molecular Characterization of the Claudin-low Intrinsic Subtype of Breast Cancer. Breast Cancer Res. 2010. 12(5):R68.
  • Scaltriti M, Eichhorn PJA, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C and Baselga J. Cyclin E amplification/overexpression a novel mechanism of trastuzumab resistance in HER2 positive breast cancer patients. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6.
  • Abell AN, Vincent NJ, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Magnuson T, Perou CM, Gomez SM, Li L, and Johnson GL. Epigenetic Regulation of Epithelial-Mesenchymal Transition in Trophoblast Stem Cells. Cell Stem Cell. 2011 May 6;8(5):525-37.
  • Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Watson MA, Allred DC, Esserman LJ, Unzeitig GW, Babiera GV, Margenthaler J, Marcom PK, Guenther JM, Leitch M, Hunt K and Olson JA. ACOSOG Z1031, a randomized phase 2 neoadjuvant comparison between letrozole, anastrozole and exemestane for postmenopausal women with ER rich stage 2/3 breast cancer: Clinical and Biomarker outcomes. J Clin Oncol. 2011 Jun 10;29(17):2342-9.
  • Harrell C, Prat A, Parker J, Fan C, He X, Carey L, Anders C, Ewend M and Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung and liver relapse. Breast Cancer Res Treat. 2011 Jun 14. [Epub ahead of print]
  • Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A. 2011 Sep 21.
  • Haakensen VD, Lingjærde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord S, Bukholm IK, Johansen T, Perou CM, Ursin G, Kristensen VN, Børresen-Dale AL, Helland A. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med Genomics. 2011 Nov 1;4(1):77
  • Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011 Dec 6;9(1):48-57.
  • Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK. Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. Breast Cancer Res. 2011 Dec 1;13(6):R125. [Epub ahead of print].
  • A Prat, CM Perou. Molecular classification of triple-negative tumors. Breast Cancer Research 2011, 13(Suppl 2):O2 (16 November 2011)
  • Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):221-6. Epub 2011 Dec 16.
  • Ma CX, Cai S, Li S, Ryan CE, Guo Z, Lin L, Hoog J, Goiffon R, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H. Targeting Chk1 in p53-Deficient Triple Negative Breast Cancer Using Human in Mouse Tumor Models. J Clin Invest. 2012 Apr 2;122(4):1541-52.
  • Eichhorn PJA, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes the TGFb receptor I and promotes oncogenesis through the activation of the TGFb signal in glioblastoma. Nat Med. Nat Med. 2012 Feb 19;18(3):429-35.
  • Xu K, Usary J, Kousis PC, Prat A, Wang D, Adams JR, Wang W,.Loch AJ, Deng T, Zhao W, Cardiff RD, Yoon K, Gaiano N, Ling1 V, Beyene J, Zacksenhaus E, Gridley T, Leong WL, Guidos C, Perou CM and Egan SE. Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-Like Breast Cancer. Cancer Cell 2012 May 25;21(5):626-41
  • Prat A, Parker JS, Fan C, Cheang MCU, Miller LD, Bergh J, Chia SKL, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol. 2012 Nov;23(11):2866-73
  • Bastien RRL, Rodríguez-Lescure A, Ebbert MTW, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Ángel Seguí M, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TON, Perou CM, Astill M, Bernard PS and Martín M. PAM50 Breast Cancer Subtyping by RT-qPCR and Agreement with Standard Clinical Molecular Scoring. BMC Med Genomics 2012 Oct 4;5:44.
  • Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012 Aug;135(1):301-6
  • The Cancer Genome Atlas Project. Comprehensive molecular portraits of human breast tumors. Nature. 2012 Oct 4;490(7418):61-70.
  • Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2012 Dec 7. [Epub ahead of print]
  • Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J. PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discov. 2012 Nov;2(11):1036-47.
  • Prat A, Cheang MC, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemical-defined Luminal A breast cancer. J Clin Oncol 2013 Jan 10;31(2):203-9
  • Bockhorn J, Dalton R, Nwachukwu C, Prat A, Yee1 K, Chang Y, Huo D, Wen Y, Huang S, Swanson KE, Qiu T, Lu J, Park S, Dolan E, Perou CM, Olopade O, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits Human Breast Tumor Chemotherapy Resistance by regulating TWF1 and IL-11. Nat Commun 2013 Jan 22;4:1393
  • Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of Basal-like and non-Basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123-33
  • Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Feb 20. [Epub ahead of print]
  • Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A. 2013 Mar 18. [Epub ahead of print]